RNS13 May 2011 11:22
extGen Group PLC
Launch of new multiplex protein plasma assay
RNS Number : 7698E
NextGen Group PLC
13 April 2011
NextGen Sciences
NextGen Sciences launches multiplex protein plasma biomarker assay for breast cancer
Ann Arbor, Michigan, US, and London, UK, 13 April 2011 - NextGen Group plc (AIM:NGG) is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its plasmabreast25 multiplex protein assay, targeting breast cancer biomarker discovery and qualification. The assay simultaneously measures 25 human plasma proteins that are thought to have potential as biomarkers in breast cancer.
Klaus Rosenau, Chairman and CEO of NextGen Group, commented, 'The release of plasmabreast25 is further indication of our commitment to developing and marketing multiplex assays for biomarker discovery in specific cancer areas. It enables us to remain focused on increasing our market share from the $600m mass spectrometry based biomarker discovery market. To ensure we continually deliver the high-quality assays that pharmaceutical, biotechnology and diagnostics companies need to inform their decision-making processes, NextGen Sciences is currently planning more such products in the near future.'
GLA
NextGen's assay is based upon its multiple reaction monitoring (MRM) mass spectrometry platform and generates high quality reproducible data that companies can use in their drug and diagnostic development programmes. NextGen expects to develop further oncology and CNS disease-focused assay panels, both as proprietary products and with other companies, through partnerships and collaborations.
- ENDS -
For more information please contact :
NextGen Group
Klaus Rosenau, Chairman and CEO
klaus.rosenau@nextgensciences.com
+49 160 551 6756
Seymour Pierce
Jonathan Wright, Nicola Marrin
+44 (0) 20 7107 8000